No Improvement in OS or PFS from Sacituzumab Govitecan Compared with Chemotherapy In Pretreated Patients with Advanced Urothelial Cancer By Ogkologos - March 24, 2025 897 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TROPiCS-04 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR EMA Recommends Granting a Marketing Authorisation for the Hybrid Medicine Imatinib July 29, 2021 Beloved Kansas City Jazz Singer Passes Away at 48 After 13-Year... December 3, 2020 Happy Nurses Month! May 3, 2021 How to Make the Most of Your Patient Portal During Cancer November 24, 2021 Load more HOT NEWS One in Five of Older Patients with EBC Treated in a... Meteorologist Uses Sign Language To Tell All Of Her Weather Forecasts New on NCI’s Websites for March 2019 Community Surprises Teen Battling Bone Cancer With Brand New Car For...
